Flavonoid compounds and uses thereof
View Patent ↗Novel flavonoid compounds having anti-oxidant activity are described. The compounds and compositions have been shown to exhibit anti-oxidant properties and are particularly useful in the treatment of ischemia and reperfusion injuries. The invention also describes a method to chemically synthesize such flavonoid compounds and test their efficacy. Such compounds and corresponding pharmaceutically acceptable derivatives and/or salts have uses in the areas of pharmaceuticals, nutraceutical, and veterinary applications.
1. A compound of the general formula I:
wherein:
═ denotes a single or double bond; and
R 1 , R 2 , R 3 , R 4 , R 5 are independently selected from H, OH or a group according to formula (Ia):
—O-L-D-E (Ia)
wherein:
O is oxygen;
i) L is a C═O group, D is an alkylene group with a chain length equivalent to about 1 to 20 carbon atoms, and E is a substituted or unsubstituted carboxylic acid group; or
ii) L and D are absent and E is an ester group according to formula (Ic):
wherein:
Q is a substituted or unsubstituted alkylene;
W is O; and X is H, a substituted or unsubstituted alkyl, benzyl, or a mono- or divalent cationic salt, or an ammonium cationic salt;
provided that at least one of R 1 , R 2 , R 3 , R 4 , R 5 is other than H or OH;
with the proviso that the compound is not 3,3′,4′,7-Tetra-O-benzylquercetin 5-[1,4,5,6-tetra-O-benzyl-2-O-(dibenzyl-oxyphosphoryl)-myo-inositol 3-succinate]; 3′,4′,7-Tri-O -benzylquercetin 3-[1,4,5,6-tetra-O-benzyl-2-O-(dibenloxyphosphoryl) myo-inositol 3-succinate]; Quercetin 5-(2-O-phosphono-myo-inositol 1-succinate) and Quercetin 3-(2-O -phosphono-myo-inositol 1-succinate).
2. A compound according to claim 1 , wherein the R 4 and R 5 are both H.
3. A compound according to claim 1 , wherein R 1 and R 2 are both OH.
4. The compound according to claim 1 , wherein ═ denotes a double bond, L and D are absent and E is an ester group according to the formula (1c):
wherein
Q is a substituted or unsubstituted alkylene;
W is O; and X is H, a substituted or unsubstituted alkyl, benzyl, or a mono- or divalent cationic salt, or an ammonium cationic salt.
5. The compound according to claim 1 , wherein Q is substituted or unsubstituted C 1 to C 6 alkylene.
6. The compound according to claim 1 , wherein X is H and Q is a butlyene group.
7. The compound according to claim 1 , wherein
═ denotes a double bond;
R 4 and R 5 are H;
R 1 and R 2 are OH;
L and D are absent and E is an ester group according to formula (Ic):
wherein:
Q is a substituted or unsubstituted alkylene;
W is O; and X is H, a mono- or divalent cationic salt, or an ammonium cationic salt.
8. The compound of claim 7 , wherein Q is substituted or unsubstituted C 1 to C 6 alkylene.
9. The compound according to claim 7 , wherein X is H and Q is a butylene group.
10. The compound according to claim 1 , wherein
═ denotes a double bond;
R 1 , R 2 and R 4 are H;
R 3 and R 5 are independently selected from H, OH or a group according to formula (Ia):
—O-L-D-E (Ia)
wherein
O is oxygen;
i) L is a C═O group, D is an alkylene group with a chain length equivalent to about 1 to 20 carbon atoms, and E is a substituted or unsubstituted carboxylic acid group, or
ii) L and D are absent and E is an ester group according to formula (Ic):
wherein
Q is a substituted or unsubstituted alkylene;
W is oxygen; and X is H, a substituted or unsubstituted alkyl, benzyl, or a mono- or divalent cationic salt, or an ammonium cationic salt;
provided that at least one of R 3 and R 5 is other than H or OH.
11. The compound according claim 10 , wherein L and D are absent and E is an ester group according to formula (Ic):
wherein
Q is a substituted or unsubstituted alkylene;
W is oxygen; and X is H, a substituted or unsubstituted alkyl, benzyl, or a mono- or divalent cationic salt, or an ammonium cationic salt.
12. The compound according to claim 11 , wherein Q is substituted or unsubstituted C 1 to C 6 alkylene.
13. The compound according to claim 11 , wherein X is H and Q is a butylene group.
14. The compound according to claim 1 which is
15. The compound according to claim 1 which is
16. A compound selected from the group comprising 3-(Benzyloxycarbonylbutylcarbonyloxy)flavone; 3-Hydroxyflavone 3-hemiadipate; 4′-(Benzyloxy)-3-(benzyloxycarbonylbutylcarbonyloxy)flavone; 4′-Hydroxyflavone 3-hemiadipate; 3′,4′-Dibenzyloxy-3-(benzyloxycarbonylbutylcarbonyloxy)flavone; 3′,4′-Dihydroxyflavone 3-hemiadipate; 3,4′-Di-(benzyloxycarbonylbutylcarbonyloxy)flavone; flavone 3,4′-bis(hemiadipate); 3,7-Di-(benzyloxycarbonylbutylcarbonyloxy)flavone; 3,7-bis(hemiadipate)flavone; 4′-Hydroxy-3-Hydroxyflavone-3-quaternary ammonium ester.
17. A pharmaceutically and/or veterinary composition comprising a pharmaceutically and/or veterinarily acceptable carrier or diluent together with a compound according to claim 1 .
18. A method of treating a disease(s) in a subject associated with the presence of reactive oxidative species (ROS), the method comprising;
administering an effective amount of at least one compound according to claim 1 .
19. The method according to claim 18 , wherein the subject in need of such treatment is at risk of developing ischaemia.
20. The method according to claim 18 , wherein the subject is suffering ischaemia and/or reperfusion injury as a result of an acute or chronic condition.
21. The method according to claim 18 , wherein the disease is selected from cerebrovascular disease, pulmonary vascular disease, atherosclerosis, artery disease, congestive heart disease, coronary disease, peripheral vascular disease, diabetes, hypertension, migraine, chronic obstructive pulmonary disease and retinal vascular disease.
22. The method according to claim 18 , wherein the disease is selected from stroke, myocardial infarction, mechanical trauma resulting from crush injury or surgery.
23. The method according to claim 18 , wherein the disease is the result of vascular surgery.
24. The method according to claim 18 , wherein the disease is the result of heart bypass and/or transplant surgery.
25. The method according to claim 18 , wherein the compound is administered to the subject before and/or during the surgery.
26. The method according to claim 18 , wherein the compounds is administered to the subject orally.
27. The method according to claim 18 , wherein the compound is
or its pharmaceutically acceptable salt.
28. A method of slowing the progression of atherosclerosis and/or coronary heart disease in a subject comprising:
administering an effective amount of at least one compound according in claim 1 .
29. The method according to claim 28 , wherein the compound is
or its pharmaceutically acceptable salt.
30. A method of at least ameliorating the damage to a subject caused by ischaemia and/or reperfusion injury, the method comprising:
administering an effective amount of at least one compound according to claim 1 .
31. The method according to claim 30 , wherein the compound is
or its pharmaceutically acceptable salt.
32. A method of at least ameliorating damage to a subject caused by the administration of a therapeutic agent, the method comprising co-administrating to a subject:
i) a therapeutic agent; and
ii) administering an effective amount of at least one compound according to claim 1 .
33. The method according to claim 32 , wherein the therapeutic agent is an oxidative therapeutic agent.
34. The method according to claim 32 , wherein the therapeutic agent is anti-cancer agent.
35. The method according to claim 32 , wherein the therapeutic agent is anthracycline and homologues thereof.
36. The method according to claim 32 , wherein the compound is
or its pharmaceutically acceptable salt.